CSN7b Activators

CSN7b, a component of the COP9 signalosome, plays a pivotal role in a myriad of cell regulation processes, prominently in the ubiquitin-proteasome pathway. The suite of chemicals termed CSN7b Activators influence pathways or processes that this signalosome engages in, thus indirectly modulating its activity. MG-132, a proteasome inhibitor, can lead to an accumulation of proteins, thereby elevating the demand for COP9 signalosome functionalities. Similarly, ALLN, a calpain and proteasome inhibitor, and Epoxomicin, a selective proteasome inhibitor, can sway COP9 signalosome functions by modulating proteasome activity. Curcumin, a naturally occurring polyphenol, affects an array of cellular pathways including proteasomal degradation, thereby having an effect on the COP9 signalosome. MLN4924, which inhibits the NEDD8-activating enzyme (NAE), can impact the function of the COP9 signalosome, given the latter's deneddylation activity. Pyr-41, by inhibiting the ubiquitin-activating enzyme E1, exerts influence on the ubiquitin-proteasome pathway, thus affecting the COP9 signalosome.

Further extending the list, Chloroquine, which impacts lysosomal pathways and autophagy, can influence the COP9 signalosome, given the latter's implications in autophagy. The sumoylation inhibitor, 2-D08, can impact the COP9 signalosome functions indirectly, considering the connection between SUMO and ubiquitin pathways. Concanamycin A, by inhibiting vacuolar type H+-ATPase, can influence the COP9 signalosome via lysosomal pathways. Bortezomib, another proteasome inhibitor, and Lactacystin, an irreversible proteasome inhibitor, both can affect the COP9 signalosome by modulating the proteasome. Lastly, Leptomycin B, an inhibitor of nuclear export, can influence the COP9 signalosome by causing a build-up of proteins.